Sign In
Buy SPRB
$49.05
-0.250 (-0.507%)
At Close: Jun 03, 2026
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
04:05pm, Thursday, 28'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences to Participate in Upcoming Conferences in June
04:05pm, Wednesday, 27'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
09:00am, Wednesday, 13'th May 2026
[url="]Spruce Biosciences, Inc.[/url] (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neur
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
08:00am, Wednesday, 13'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
11:45pm, Monday, 20'th Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Monday, 20'th Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade
10:56am, Friday, 03'rd Apr 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 181.2% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?
10:56am, Wednesday, 18'th Mar 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 208.3% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
07:05am, Monday, 09'th Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
07:00am, Monday, 09'th Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference
04:30am, Tuesday, 03'rd Mar 2026
Executives from Spruce Biosciences (NASDAQ: SPRB) outlined regulatory plans, clinical data highlights, and commercial considerations for the company's lead program in Sanfilippo syndrome type B (MPS I
Spruce Biosciences to Present at Upcoming Investor Conferences in March
04:05pm, Monday, 02'nd Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
07:00am, Wednesday, 18'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
04:05pm, Tuesday, 17'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
